26 Mar 2018 07:00
Silence Therapeutics to Present at Upcoming Scientific Conferences in March and April 2018
London, 26th March 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that that the company is scheduled to present at the following scientific conferences in March and April 2018.
Third Annual Oligonucleotide & Peptide Therapeutics (OPT)
March 26-28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US
Marie Lindholm, Head of Technology Innovation, will present on Tuesday March 27 at 1.20pm EDT. The presentation is entitled 'Development of Novel Therapies Using Advanced GalNAc-siRNA Technology'.
Drug Discovery for Rare Diseases Symposium at OPT Congress
March 28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US
Torsten Hoffmann, COO, will present a case study on the company and its science entitled 'Identification and Development of SLN124, a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron Overload Disorders' at 4.35pm EDT.
4th Annual Oligo 2018 Oxford
April 10, 2018, St Edmund Hall, Oxford, UK
Adrien Weingaertner, Group Leader, Drug Delivery, will make a presentation at 5.30pm BST. The presentation is entitled 'Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders'.
9th Clinical Trials Innovation Programme
April, 26-27, 2018, Höchster Hof Hotel GmbH, Frankfurt, Germany
Manuela Aleku, Head of Non-Clinical Development, will be presenting on Thursday April 26, 2018 at 9am CEST.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
|
Tel: +44 (0)20 7418 8900 |
Media Enquiries: Optimum Strategic Communications Mary Clark/ Eva Haas/Hollie Vile silence@optimumcomms.com
|
Tel: +44 (0) 20 3714 1788 |
IR Enquires - US Burns McClellan John Grimaldi | Tel: +1 (212) 213 0006 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/
SLN.L (SLN)